Skip to main content
. Author manuscript; available in PMC: 2016 Dec 15.
Published in final edited form as: Biochem Pharmacol. 2015 Sep 21;98(4):564–572. doi: 10.1016/j.bcp.2015.09.014

Figure 6.

Figure 6

Aspirin and NOSH-aspirin reduce LPS-induced fever, raise the threshold for hyperalgesia, and show anti-platelet activity. Panel A: LPS (50 μg/kg, ip) was administered to the rats one hour before administration aspirin and NOSH-aspirin as described in Section 2.7. Core body temperature was recorded at 30 min and thereafter hourly for 5 h. Results are mean ± SEM for 5 rats in each group, *P < 0.01 vs vehicle for both aspirin and NOSH-aspirin from 1–5 h.

Panel B: Mechanical pain threshold was increased in a time-dependent manner by aspirin and NOSH-aspirin as detailed in Section 2.9. Results are mean ± SEM for 5 rats in each group. *P < 0.05 vs vehicle for aspirin and NOSH-aspirin 2–5 h.

Panel C: Aspirin and NOSH-aspirin were equally effective in inhibiting human platelet aggregation, protocol as described in Section 2.10. Results are mean ± range for two individuals.